OR
ORMP.US Oramed Pharmaceuticals Inc
- Market cap
- USD 170M
- P/E
- 0.9x
- P/B
- 0.50x
- ROE
- 53.0%
- Dividend yield
- 6.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ORMP.US undervalued?
Graham numberThe Graham number of Oramed Pharmaceuticals Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oramed Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Oramed Pharmaceuticals Inc yet.
Oramed Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquarter…
Full company profileOramed Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oramed Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 641K | 2.46M | 2.45M | 2.70M | 2.71M | 2.70M | 2.70M | 1.34M | 0.00 | 2.00M | 0.00 |
| Gross Profit | 151K | 2.27M | 2.36M | 2.61M | 2.71M | 2.70M | 2.70M | 1.34M | -193K | 13.0K | -40.0K |
| Operating Income | -10.0M | -10.8M | -13.5M | -14.6M | -11.8M | -24.2M | -40.6M | -15.8M | -12.8M | -15.1M | -14.0M |
| EBITDA | -9.99M | -10.8M | -13.5M | -14.2M | -11.8M | -24.1M | -40.5M | 7.32M | -14.9M | 75.4M | 168M |
| Net Income | -11.0M | -10.5M | -12.7M | -14.4M | -11.5M | -22.2M | -37.8M | 5.53M | -19.1M | 64.1M | 180M |
| EPS | -0.87 | -0.79 | -0.86 | -0.82 | -0.56 | -0.78 | -0.97 | 0.14 | -0.47 | 1.51 | 4.18 |
| Balance Sheet | |||||||||||
| Total Assets | 42.8M | 38.7M | 47.4M | 34.7M | 44.6M | 128M | 162M | 221M | 155M | 231M | 401M |
| Total Liabilities | 16.6M | 19.5M | 16.3M | 15.3M | 11.8M | 11.5M | 10.5M | 57.7M | 9.93M | 31.1M | 61.8M |
| Shareholders' Equity | 26.2M | 19.2M | 31.1M | 19.4M | 32.9M | 116M | 152M | 164M | 146M | 200M | 339M |
| Cash & Short-term Investments | 31.0M | 20.1M | 30.5M | 32.3M | 39.9M | 94.1M | 156M | 162M | 142M | 126M | 29.5M |
| Total Debt | - | - | - | - | 75.0K | 533K | 894K | 51.6M | 372K | 825K | 1.53M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 4.66M | -5.83M | -14.7M | -12.9M | -12.4M | -21.2M | -28.7M | -10.3M | -8.41M | -9.15M | -3.59M |
| Capital Expenditure | 9.00K | 7.00K | 5.00K | 15.0K | 82.0K | 375K | 496K | 254K | 18.0K | 1.93M | 14.7K |
| Free Cash Flow | 4.65M | -5.84M | -14.7M | -13.0M | -12.5M | -21.6M | -29.2M | -10.5M | -8.43M | -11.1M | -3.60M |
| Ratios | |||||||||||
| ROE | -41.9% | -54.5% | -40.9% | -74.0% | -35.0% | -19.2% | -24.9% | 3.4% | -13.0% | 32.1% | 53.0% |
| ROA | -25.6% | -27.1% | -26.9% | -41.4% | -25.8% | -17.4% | -23.4% | 2.5% | -12.3% | 27.7% | 44.9% |
| Net Profit Margin | -1,710.5% | -426.7% | -519.7% | -531.1% | -424.8% | -822.7% | -1,397.1% | 412.3% | - | 3,202.5% | - |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.01x | 0.32x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oramed Pharmaceuticals Inc dividends
- Dividend yield
- 6.41%
- Forward dividend
- 0.25 USD
- Payout ratio
- 17.0%
- Ex-dividend date
- Jan 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 10.9M | 0.26 | 17.0% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on Jan 23, 2013.
Who owns Oramed Pharmaceuticals Inc
- Insiders 20.56%
- Institutions 46.26%
- Public & others 33.18%
- Shares outstanding 43.5M
- Free float 28.1M
Top funds holding ORMP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 822K | 1.90% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 378K | 0.88% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 318K | 0.74% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 203K | 0.47% | +3.12% | Sep 2026 |
| iShares Micro-Cap ETF | 107K | 0.25% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 83.6K | 0.19% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 63.6K | 0.15% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 60.2K | 0.14% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 55.6K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Small Cap Value Index | 50.4K | 0.12% | 0.00% | Aug 2026 |
| Nuveen Small Cap Blend Idx R6 | 46.4K | 0.11% | 0.00% | Sep 2026 |
| Dimensional US Small Cap ETF | 40.5K | 0.09% | 0.00% | Oct 2026 |
| Dimensional US Core Equity 2 ETF | 36.5K | 0.08% | 0.00% | Oct 2026 |
| EQ/2000 Managed Volatility IB | 33.5K | 0.08% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 Value ETF | 33.0K | 0.08% | +4.51% | Sep 2026 |
| Nationwide Bailard Sm Cp Val M | 32.5K | 0.08% | 0.00% | Sep 2026 |
| Xtrackers Russell 2000 ETF 1C | 29.2K | 0.07% | -6.30% | Sep 2026 |
| Datamira LS World Fund F EUR Acc | 28.3K | 0.07% | +10.37% | Oct 2026 |
| LVIP SSgA Small Cap Index Std | 25.7K | 0.06% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 2 Instl | 23.3K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding ORMP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Mercer Global Advisors Inc. | 3.81M | 8.81% | +99.45% | Jun 2026 |
| Aquamarine Financial (Cayman) Ltd | 2.51M | 5.81% | +18.93% | Jun 2026 |
| Gem Investment Advisors, LLC | 2.00M | 4.62% | +21.87% | Jun 2026 |
| BlackRock Inc | 1.61M | 3.72% | +1,644.31% | Jun 2026 |
| Murchinson Ltd. | 1.29M | 2.98% | -1.90% | Jun 2026 |
| BML Capital Management LLC | 884K | 2.05% | +2.09% | Sep 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 579K | 1.34% | -3.68% | Jun 2026 |
| Geode Capital Management, LLC | 501K | 1.16% | +1,961.98% | Jun 2026 |
| Renaissance Technologies Corp | 294K | 0.68% | +60.10% | Sep 2026 |
| The Goldman Sachs Group Inc | 253K | 0.59% | 0.00% | Jun 2026 |
| State Street Corp | 242K | 0.56% | 0.00% | Jun 2026 |
| Rathbone Brothers PLC | 233K | 0.54% | -50.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 230K | 0.53% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 211K | 0.49% | +4.26% | Sep 2026 |
| Northern Trust Corp | 185K | 0.43% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 166K | 0.38% | +5.34% | Jun 2026 |
| Bank of America Corp | 151K | 0.35% | +3.11% | Jun 2026 |
| STRS OHIO | 134K | 0.31% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 113K | 0.26% | +115.74% | Jun 2026 |
| O'Shaughnessy Asset Management LLC | 103K | 0.24% | -11.52% | Jun 2026 |
Oramed Pharmaceuticals Inc company profile
- Company name
- Oramed Pharmaceuticals Inc
- Ticker
- ORMP.US
- Exchange
- USA Stocks
- Listed since
- Apr 21, 2006
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1185 Avenue of the Americas, New York, NY, United States, 10036
- Phone
- 844 967 2633
- Website
- oramed.com
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Oramed Pharmaceuticals Inc management
4- Mr. Nadav Kidron Esq.President, CEO & Executive Chairman · born 1974
- Mr. Joshua HexterChief Operating & Business Officer · born 1970
- Dr. Miriam Kidron Ph.D.Chief Scientific Officer & Director · born 1940
- Mr. Avraham GabayCFO, Treasurer & Secretary · born 1985